 CD40 Antigens
"CD40 Antigens" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Members of the tumor necrosis factor receptor superfamily with specificity for CD40 LIGAND. They are found on mature B-LYMPHOCYTES, some EPITHELIAL CELLS; and lymphoid DENDRITIC CELLS. Evidence suggests that CD40-dependent activation of B-cells is important for generation of memory B-cells within the germinal centers. Mutations in the CD40 antigen gene result in HYPER-IGM IMMUNODEFICIENCY SYNDROME, TYPE 3. Signaling of the receptor occurs through its association with TNF RECEPTOR-ASSOCIATED FACTORS.
| Descriptor ID |
D019013
|
| MeSH Number(s) |
D12.776.543.750.705.852.760.097 D23.050.301.264.051.140 D23.101.100.150.140
|
| Concept/Terms |
CD40 Antigens- CD40 Antigens
- TNFRSF5 Receptor
- Receptor, TNFRSF5
- CDw40 Antigen
- Antigen, CDw40
- Tumor Necrosis Factor Receptor Superfamily, Member 5
- CD40 Antigen
- Antigen, CD40
- Antigens, CD40
|
Below are MeSH descriptors whose meaning is more general than "CD40 Antigens".
- Chemicals and Drugs [D]
- Amino Acids, Peptides, and Proteins [D12]
- Proteins [D12.776]
- Membrane Proteins [D12.776.543]
- Receptors, Cell Surface [D12.776.543.750]
- Receptors, Immunologic [D12.776.543.750.705]
- Receptors, Cytokine [D12.776.543.750.705.852]
- Receptors, Tumor Necrosis Factor [D12.776.543.750.705.852.760]
- CD40 Antigens [D12.776.543.750.705.852.760.097]
- Biological Factors [D23]
- Antigens [D23.050]
- Antigens, Surface [D23.050.301]
- Antigens, Differentiation [D23.050.301.264]
- Antigens, Differentiation, B-Lymphocyte [D23.050.301.264.051]
- CD40 Antigens [D23.050.301.264.051.140]
- Biomarkers [D23.101]
- Antigens, Differentiation [D23.101.100]
- Antigens, Differentiation, B-Lymphocyte [D23.101.100.150]
- CD40 Antigens [D23.101.100.150.140]
Below are MeSH descriptors whose meaning is more specific than "CD40 Antigens".
This graph shows the total number of publications written about "CD40 Antigens" by people in this website by year, and whether "CD40 Antigens" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2000 | 1 | 0 | 1 | | 2001 | 0 | 1 | 1 | | 2002 | 2 | 1 | 3 | | 2003 | 1 | 3 | 4 | | 2004 | 1 | 1 | 2 | | 2005 | 1 | 0 | 1 | | 2006 | 4 | 0 | 4 | | 2007 | 2 | 0 | 2 | | 2008 | 3 | 1 | 4 | | 2009 | 2 | 0 | 2 | | 2010 | 1 | 1 | 2 | | 2012 | 3 | 2 | 5 | | 2013 | 3 | 0 | 3 | | 2014 | 4 | 4 | 8 | | 2015 | 1 | 3 | 4 | | 2016 | 1 | 1 | 2 | | 2017 | 2 | 0 | 2 | | 2019 | 1 | 1 | 2 | | 2020 | 1 | 0 | 1 | | 2021 | 2 | 0 | 2 | | 2023 | 1 | 1 | 2 |
To return to the timeline, click here.
Below are the most recent publications written about "CD40 Antigens" by people in Profiles.
-
Frank FM, Wagner DH, Postan M, Petray PB. Importance of CD40/CD40 dyad in the course of infection with Trypanosoma cruzi: Impact of its inhibition. Microb Pathog. 2023 Oct; 183:106327.
-
Vaitaitis GM, Wagner DH. Modulating CD40 and integrin signaling in the proinflammatory nexus using a 15-amino-acid peptide, KGYY15. J Biol Chem. 2023 05; 299(5):104625.
-
Yalamanoglu A, Dubach IL, Schulthess N, Ingoglia G, Swindle DC, Humar R, Schaer DJ, Buehler PW, Irwin DC, Vallelian F. Agonistic Anti-CD40 Antibody Triggers an Acute Liver Crisis With Systemic Inflammation in Humanized Sickle Cell Disease Mice. Front Immunol. 2021; 12:627944.
-
Burrack AL, Rollins MR, Spartz EJ, Mesojednik TD, Schmiechen ZC, Raynor JF, Wang IX, Kedl RM, Stromnes IM. CD40 Agonist Overcomes T Cell Exhaustion Induced by Chronic Myeloid Cell IL-27 Production in a Pancreatic Cancer Preclinical Model. J Immunol. 2021 03 15; 206(6):1372-1384.
-
Zou M, Zhang X, Jiang D, Zhao Y, Wu T, Gong Q, Su H, Wu D, Moreland L, Li G. Transcriptional Regulation of CD40 Expression by 4 Ribosomal Proteins via a Functional SNP on a Disease-Associated CD40 Locus. Genes (Basel). 2020 12 21; 11(12).
-
Vaitaitis GM, Olmstead MH, Waid DM, Carter JR, Wagner DH. CD40-targeted peptide proposed for type 1 diabetes therapy lacks relevant binding affinity to its cognate receptor. Reply to Pagni PP, Wolf A, Lo Conte M et al [letter]. Diabetologia. 2019 09; 62(9):1730-1731.
-
Vaitaitis GM, Yussman MG, Wagner DH. A CD40 targeting peptide prevents severe symptoms in experimental autoimmune encephalomyelitis. J Neuroimmunol. 2019 07 15; 332:8-15.
-
Woolaver RA, Wang X, Dollin Y, Xie P, Wang JH, Chen Z. TRAF2 Deficiency in B Cells Impairs CD40-Induced Isotype Switching That Can Be Rescued by Restoring NF-?B1 Activation. J Immunol. 2018 12 01; 201(11):3421-3430.
-
Vaitaitis GM, Waid DM, Yussman MG, Wagner DH. CD40-mediated signalling influences trafficking, T-cell receptor expression, and T-cell pathogenesis, in the NOD model of type 1 diabetes. Immunology. 2017 10; 152(2):243-254.
-
Vaitaitis GM, Yussman MG, Waid DM, Wagner DH. Th40 cells (CD4+CD40+ Tcells) drive a more severe form of Experimental Autoimmune Encephalomyelitis than conventional CD4 T cells. PLoS One. 2017; 12(2):e0172037.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|